- Goals of Treatment, Indication, and Treatment for Chronic Hepatits C
-
Paik SW
- KMID: 1767541
- Korean J Gastroenterol.
- 2008 Jun;51(6):368-371.
Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatic fibrosis worldwide. Up to 85% of individuals infected with HCV develop chronic infection, which can progress to... -
- CITED
-
- Close
- SHARE
-
- Close
- A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C
-
Shin MK, Kim TH, Ju K, Ha CY, Min HJ, Jung WT, Lee OJ
- KMID: 1374966
- Korean J Hepatol.
- 2009 Sep;15(3):370-374.
- doi: 10.3350/kjhep.2009.15.3.370
Combination therapy of pegylated interferon alpha and ribavirin has been associated with various adverse effects, but sudden-onset hearing loss is uncommon. We report a 60-year-old male patient who developed sudden-onset... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation
-
Kim BK, Kwon SY, Ko SY, Choe WH, Lee CH, Han HS, Chang SH
- KMID: 1073304
- Korean J Hepatol.
- 2008 Dec;14(4):519-524.
- doi: 10.3350/kjhep.2008.14.4.519
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was... -
- CITED
-
- Close
- SHARE
-
- Close
- Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
-
Lee TH, Lee KO, Kim YS, Kim SM, Huh KC, Choi YW, Kang YW
- KMID: 1792063
- Korean J Intern Med.
- 2014 May;29(3):370-374.
- doi: 10.3904/kjim.2014.29.3.370
Various adverse events have been reported during combination therapy with pegylated (PEG)-interferon-alpha and ribavirin, although opportunistic infections, especially cryptococcal meningitis, are very rare. A 61-year-old woman complained of headaches and... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence of and risk factors for thyroid dysfunction during peginterferon alpha and ribavirin treatment in patients with chronic hepatitis C
-
Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH
- KMID: 2381583
- Korean J Intern Med.
- 2015 Nov;30(6):792-800.
- doi: 10.3904/kjim.2015.30.6.792
BACKGROUND/AIMS: Thyroid dysfunction (TD) is more likely to occur in patients with chronic hepatitis C (CHC) and is particularly associated with interferon (IFN) treatment. The purpose of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study
-
Kim JI, Kim SH, Lee BS, Lee HY, Lee TH, Kang YW, Lee HI, Kim AN, Nam SW, Park BC, Chae HB, Kim SB, Song IH, Park JY, Kim HS
- KMID: 1073301
- Korean J Hepatol.
- 2008 Dec;14(4):493-502.
- doi: 10.3350/kjhep.2008.14.4.493
BACKGROUNDS/AIMS: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of... -
- CITED
-
- Close
- SHARE
-
- Close
